Sanofi says U.S. FDA to fast track Fabry therapy review

PARIS (Reuters) – French drugmaker Sanofi said on Tuesday that the U.S. Food and Drug Administration has agreed to speed up the review of its drug application for a new Fabry disease treatment. Sanofi said its Genzyme unit was enrolling patients in a mid-stage Phase IIa trial of the “GZ/SAR402671” therapy. Fabry disease is an inherited, potentially fatal disorder characterized by the buildup of a particular type of fat that results in cell damage, leading to pain, hearing loss, kidney failure, heart attacks and strokes. (Reporting by James Regan; Editing by Emelia Sithole-Matarise)
Go to Source